This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Diabetic Under 70 (Diabetics Below 70)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: August 14, 2007
Last updated: October 29, 2014
Last verified: October 2014
A screening project of diabetics with a very high cardiovascular risk (e.g. diabetes plus coronary heart disease) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <70mg/dl for such patients with very high risk) are screened. The doctors therapy decisions after the screening will be documented and 8-10 weeks later the lipid profile of each patient will be evaluated again. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Diabetes Hyperlipidemia Atherosclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diabetic Under 70 (Diabetics Below 70)

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Cholesterol levels [ Time Frame: After 4 weeks ]
    Cholesterol levels from high risk patients after 4 weeks of cholesterol-lowering drug therapy under target values

Enrollment: 685
Study Start Date: July 2007
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Patients at very high risk
Patients at high risk
Patients at medium risk
Patients at low risk


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Male and female secondary prevention patients with: coronary disease with event: acute coronary syndrome, status post MI, PTCA, CABG, angiographically verified), PAVK (min. IIb or S.p. revascularization), stroke/TIA, carotis-plaque (asymptomatic min. 70% or S.p. revascularization), Diabetes Mellitus (type I, II)

Inclusion Criteria:

  • Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.) who already receive cholesterol-lowering therapy

Exclusion Criteria:

  • Diabetics w/o CVD; diabetics who do not receive cholesterol-lowering therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00516204

Research Site
Vienna, Austria
Sponsors and Collaborators
Study Chair: Michael Roden, MD Chairs of the Austrian Diabetes Society
  More Information

Responsible Party: AstraZeneca Identifier: NCT00516204     History of Changes
Other Study ID Numbers: NIS-CAT-CRE-2007/3
Study First Received: August 14, 2007
Last Updated: October 29, 2014

Keywords provided by AstraZeneca:
Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.)

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases processed this record on August 17, 2017